Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy
Aim. To investigate whether tumor size is a reasonable indication for adjuvant chemotherapy for T3-4aN0M0 gastric cancer patients after D2 gastrectomy. Method. We performed a retrospective study of 269 patients with a histological diagnosis of T3-4aN0M0 stage gastric cancer who underwent D2 radical...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Gastroenterology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2017/4928736 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832548127172722688 |
---|---|
author | Shi Chen Li-Ying Ou-Yang Run-Cong Nie Yuan-Fang Li Jun Xiang Zhi-Wei Zhou Ying-Bo Chen Jun-Sheng Peng |
author_facet | Shi Chen Li-Ying Ou-Yang Run-Cong Nie Yuan-Fang Li Jun Xiang Zhi-Wei Zhou Ying-Bo Chen Jun-Sheng Peng |
author_sort | Shi Chen |
collection | DOAJ |
description | Aim. To investigate whether tumor size is a reasonable indication for adjuvant chemotherapy for T3-4aN0M0 gastric cancer patients after D2 gastrectomy. Method. We performed a retrospective study of 269 patients with a histological diagnosis of T3-4aN0M0 stage gastric cancer who underwent D2 radical surgery at the Sun Yat-sen University Cancer Center or the Sixth Affiliated Hospital of Sun Yat-sen University between January 2006 and December 2010. The follow-up lasted until June of 2015. Chi-square tests and Kaplan-Meier methods were employed to compare the clinicopathological variables and prognoses. Result. For this group of patients, univariate analyses revealed that tumor size (p<0.001), pathological T stage (p<0.001), and tumor location (p=0.025) were significant prognostic factors. Adjuvant chemotherapy did not exhibit prognostic benefits. For patients with tumors larger than 5 cm, univariate analysis revealed that tumor location (p=0.007), Borrmann type (p=0.039), postoperative chemotherapy (p=0.003), and pathological T stage (p<0.001) were significant prognostic factors. Multivariate analysis revealed that postoperative chemotherapy and pathological T stage were independent prognostic factors. Conclusion. Our results imply that tumor size should be a critical factor in the decision to utilize adjuvant chemotherapy for T3-4aN0M0 gastric cancer patients after D2 gastrectomy. Additional randomized controlled trials are required before this conclusion can be considered definitive. |
format | Article |
id | doaj-art-7d21b2faafbf4bb89f7f8d5d87b2565a |
institution | Kabale University |
issn | 1687-6121 1687-630X |
language | English |
publishDate | 2017-01-01 |
publisher | Wiley |
record_format | Article |
series | Gastroenterology Research and Practice |
spelling | doaj-art-7d21b2faafbf4bb89f7f8d5d87b2565a2025-02-03T06:42:14ZengWileyGastroenterology Research and Practice1687-61211687-630X2017-01-01201710.1155/2017/49287364928736Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 GastrectomyShi Chen0Li-Ying Ou-Yang1Run-Cong Nie2Yuan-Fang Li3Jun Xiang4Zhi-Wei Zhou5Ying-Bo Chen6Jun-Sheng Peng7The 6th Affiliated Hospital, Sun Yat-sen University, No. 26, Yuancun Erheng Road, Tianhe District, 510655 Guangzhou, ChinaDepartment of Intensive Care Unit, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, 510060 Guangzhou, ChinaDepartment of Gastropancreatic Surgery, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, 510060 Guangzhou, ChinaDepartment of Gastropancreatic Surgery, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, 510060 Guangzhou, ChinaThe 6th Affiliated Hospital, Sun Yat-sen University, No. 26, Yuancun Erheng Road, Tianhe District, 510655 Guangzhou, ChinaDepartment of Gastropancreatic Surgery, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, 510060 Guangzhou, ChinaDepartment of Gastropancreatic Surgery, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, 510060 Guangzhou, ChinaThe 6th Affiliated Hospital, Sun Yat-sen University, No. 26, Yuancun Erheng Road, Tianhe District, 510655 Guangzhou, ChinaAim. To investigate whether tumor size is a reasonable indication for adjuvant chemotherapy for T3-4aN0M0 gastric cancer patients after D2 gastrectomy. Method. We performed a retrospective study of 269 patients with a histological diagnosis of T3-4aN0M0 stage gastric cancer who underwent D2 radical surgery at the Sun Yat-sen University Cancer Center or the Sixth Affiliated Hospital of Sun Yat-sen University between January 2006 and December 2010. The follow-up lasted until June of 2015. Chi-square tests and Kaplan-Meier methods were employed to compare the clinicopathological variables and prognoses. Result. For this group of patients, univariate analyses revealed that tumor size (p<0.001), pathological T stage (p<0.001), and tumor location (p=0.025) were significant prognostic factors. Adjuvant chemotherapy did not exhibit prognostic benefits. For patients with tumors larger than 5 cm, univariate analysis revealed that tumor location (p=0.007), Borrmann type (p=0.039), postoperative chemotherapy (p=0.003), and pathological T stage (p<0.001) were significant prognostic factors. Multivariate analysis revealed that postoperative chemotherapy and pathological T stage were independent prognostic factors. Conclusion. Our results imply that tumor size should be a critical factor in the decision to utilize adjuvant chemotherapy for T3-4aN0M0 gastric cancer patients after D2 gastrectomy. Additional randomized controlled trials are required before this conclusion can be considered definitive.http://dx.doi.org/10.1155/2017/4928736 |
spellingShingle | Shi Chen Li-Ying Ou-Yang Run-Cong Nie Yuan-Fang Li Jun Xiang Zhi-Wei Zhou Ying-Bo Chen Jun-Sheng Peng Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy Gastroenterology Research and Practice |
title | Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy |
title_full | Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy |
title_fullStr | Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy |
title_full_unstemmed | Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy |
title_short | Tumor Size Is a Critical Factor in Adjuvant Chemotherapy for T3-4aN0M0 Gastric Cancer Patients after D2 Gastrectomy |
title_sort | tumor size is a critical factor in adjuvant chemotherapy for t3 4an0m0 gastric cancer patients after d2 gastrectomy |
url | http://dx.doi.org/10.1155/2017/4928736 |
work_keys_str_mv | AT shichen tumorsizeisacriticalfactorinadjuvantchemotherapyfort34an0m0gastriccancerpatientsafterd2gastrectomy AT liyingouyang tumorsizeisacriticalfactorinadjuvantchemotherapyfort34an0m0gastriccancerpatientsafterd2gastrectomy AT runcongnie tumorsizeisacriticalfactorinadjuvantchemotherapyfort34an0m0gastriccancerpatientsafterd2gastrectomy AT yuanfangli tumorsizeisacriticalfactorinadjuvantchemotherapyfort34an0m0gastriccancerpatientsafterd2gastrectomy AT junxiang tumorsizeisacriticalfactorinadjuvantchemotherapyfort34an0m0gastriccancerpatientsafterd2gastrectomy AT zhiweizhou tumorsizeisacriticalfactorinadjuvantchemotherapyfort34an0m0gastriccancerpatientsafterd2gastrectomy AT yingbochen tumorsizeisacriticalfactorinadjuvantchemotherapyfort34an0m0gastriccancerpatientsafterd2gastrectomy AT junshengpeng tumorsizeisacriticalfactorinadjuvantchemotherapyfort34an0m0gastriccancerpatientsafterd2gastrectomy |